Cathy Srebalus-Barnes, PhD Joins Hospira as Senior Director, Bioanalytical Sciences

Former Director, Bioproduct Analytical Development at

Eli Lilly and Company

Life Science Partner announces the recruitment of Cathy Srebalus-Barnes, PhD, an experienced bioanalytical executive, to become Senior Director, Bioanalytical Sciences, Global Biologics R&D for Hospira, Inc.

Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In her new role at Hospira, Inc., Srebalus-Barnes will lead a global scientific team responsible for bioanalytical method development and bioanalytical characterization activities supporting Hospira’s growing biosimilars pipeline.

Srebalus-Barnes has spent much of her career at Eli Lilly and Company, where she was most recently responsible for leading three teams of scientists that included Analytical Development, Trace Analysis and Bioassay groups.  She oversaw the complete downstream process for Phase II – ready for III preparation for therapeutic biotechnology products in clinical and commercial development.  Previously, Srebalus-Barnes served as Director, Bioprocess Virology and Purification Development, where she was responsible for two groups managing the purification process development and viral safety procedures for all biotechnology products in development.

Barnes earned a Bachelor of Science Degree in Chemistry from West Virginia University and her Doctorate from Indiana University in Analytical Chemistry.